mirage

Generic Drug Policies in Latin America

LACER-LACEA/Manakin Repository

Show simple item record

dc.contributor.author López Linares, Roberto
dc.contributor.author Homedes, Núria
dc.contributor.author Ugalde, Antonio
dc.date.accessioned 2013-05-29T17:51:59Z
dc.date.available 2013-05-29T17:51:59Z
dc.date.issued 2005-03
dc.identifier.uri http://hdl.handle.net/10986/13639
dc.description.abstract The World Health Organization and pharmaceutical experts have recommended that Generic Drug Policies be implemented to improve the availability of affordable medicines. This document reports on the status of generic drug policies in Latin America. The data presented are based on several sources: a survey conducted in 2003, archival information, and official health and pharmaceutical policy documents. The survey revealed that countries use different definitions for the terms generic and bioequivalence severely curtailing the ability to make comparisons across countries. There is also ample variability in the periods allowed for drug registration and registration charges. Although most countries in the region are becoming increasingly dependent on pharmaceutical imports, many have sizeable local pharmaceutical manufacturing capacity. The need to adopt common definitions for technical terms, the urgency of improving quality controls and the importance of strengthening generic drug programs are highlighted. en
dc.language English
dc.language.iso en_US
dc.publisher World Bank, Washington, DC
dc.relation.ispartofseries Health, Nutrition and Population (HNP) discussion paper;
dc.rights CC BY 3.0 IGO
dc.rights.uri http://creativecommons.org/licenses/by/3.0/igo/
dc.subject HOSPITALS
dc.subject LATIN AMERICAN
dc.subject PHARMACEUTICAL POLICIES
dc.subject PRESCRIPTIONS
dc.subject BIOEQUIVALENCE
dc.subject PHYSICIANS
dc.subject SAFETY
dc.subject PHARMACISTS
dc.subject ESSENTIAL DRUGS
dc.subject PHARMACEUTICAL POLICY
dc.subject GMP
dc.subject PHARMACEUTICAL REGISTRATION
dc.subject PHARMACEUTICAL PRODUCTION
dc.subject HEALTH SERVICES
dc.subject GOOD MANUFACTURING PRACTICES
dc.subject STRATEGIC PLANNING
dc.subject QUALITY
dc.subject BRAND NAME
dc.subject NATIONAL DRUG POLICIES
dc.subject PHARMACEUTICAL INDUSTRY
dc.subject BRAND NAME DRUGS
dc.subject COUNTERFEIT DRUGS
dc.subject BRANDED GENERIC DRUGS
dc.subject BRAND NAMES
dc.subject SUPPLIERS
dc.subject PROCUREMENT
dc.subject PHARMACY
dc.subject QUALITY ASSURANCE
dc.subject PHARMACEUTICAL MANUFACTURING
dc.subject DRUG POLICIES
dc.subject ACCESS TO PHARMACEUTICALS
dc.subject DRUG POLICY
dc.subject GENERIC PRODUCTS
dc.subject MARKET VALUE
dc.subject PATIENTS
dc.subject POLICY DOCUMENTS
dc.subject LOCAL PRODUCTION
dc.subject LABORATORIES
dc.subject PRIVATE SECTOR
dc.subject CLINICAL TRIALS
dc.subject HEALTH POLICY
dc.subject RETAIL
dc.subject PHARMACEUTICALS
dc.subject HEALTH CARE
dc.subject GENERIC SUBSTITUTION
dc.subject NUTRITION
dc.subject MEDICINE
dc.subject PHARMACOLOGY
dc.subject PHARMACEUTICAL PRODUCTS
dc.subject DRUG MANUFACTURING
dc.subject DRUG PRICES
dc.subject MEDICINES
dc.subject ACTIVE INGREDIENTS
dc.subject NEW PRODUCT DEVELOPMENT
dc.subject HUMAN DEVELOPMENT
dc.subject PUBLIC HEALTH
dc.subject LAWS
dc.subject PUBLIC SECTOR
dc.subject PRICE CONTROLS
dc.subject SALES
dc.subject COMMERCIALIZATION
dc.subject GENERIC DRUGS
dc.title Generic Drug Policies in Latin America en
dc.rights.holder World Bank


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

CC BY 3.0 IGO Except where otherwise noted, this item's license is described as CC BY 3.0 IGO

Search LACER-LACEA


Browse

My Account